| From MAIA's closing valuation on Monday, this $10.27 target suggests an upside potential of over 450%!
Critical Report Info:
Valuation: Recent updates further de-risk the THIO program in third-line NSCLC. The Phase 2 THIO-101 dataset now shows a median overall survival of 17.8 months in the intent-to-treat cohort with a generally tolerable safety profile, and a confirmed partial response after 20 months of therapy supports durability. Fast Track designation for ateganosine in NSCLC and a master clinical supply agreement with Roche to evaluate the THIO–atezolizumab sequence enhance the regulatory path and partnering visibility. We continue to expect initiation of the pivotal THIO-104 study in the second half of 2025 with an accelerated approval filing targeted for 2026, contingent on THIO-101 outcomes, while planned multitumor studies expand the addressable opp. We have revised our valuation model to incorporate the most recent financial results, updated share count, and re-evaluated the comparable company analysis, yielding a valuation of $10.27 per share, contingent on successful execution by the company.
#2. A Major Analyst Target Suggest Serious Upside Potential (Triple-Digit!).
Noble Capital Markets - $14.00 Target - (Potential upside of 650+% from Tuesday's close.)
Key Report Details:
Conclusion. Roche becomes the third pharmaceutical company to make a supply agreement with MAIA to test a checkpoint inhibitor in combination with THIO. We believe this shows that potential partners have noticed the data showing improved overall survival (OS), progression free survival (PFS), and the side effect profile. Clinical data from the three of the eight approved checkpoint inhibitors could make bidding for a marketing partnership more competitive. We are reiterating our Outperform rating and $14 price target.
#3. MAIA Has A Relatively Low Float (Volatility Potential May Be Explosive).
Sporting a float of roughly 28.32Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash.
#4. MAIA Biotechnology Showcases Significant Success Strengthening Survival Statistics In Study.
MAIA Biotechnology reported strong Phase 2 THIO-101 results in advanced NSCLC, showing ateganosine plus cemiplimab achieved median progression-free survival of 5.6 months—over twice the standard of care’s 2.5 months—and median overall survival of 17.8 months.
Two patients completed 33 treatment cycles, highlighting durability and low toxicity.
CEO Vlad Vitoc emphasized the significance of extended dosing and superior efficacy as the expansion trial began enrolling in July 2025, aiming to further validate ateganosine’s potential as a breakthrough treatment option for patients with few remaining therapeutic alternatives.
#5. Major Advancement Marks MAIA Biotechnology’s Monumental Milestone In Medical Innovation.
MAIA Biotechnology received a $2.3Mn NIH grant to expand its THIO-101 Phase 2 trial of ateganosine for third-line advanced non-small cell lung cancer (NSCLC).
The funding supports U.S. patient enrollment from 2025 to 2027 following FDA IND clearance.
Early results show median overall survival of 17.8 months versus the 5–6 months seen with standard chemotherapy, underscoring ateganosine’s promise as a breakthrough immunotherapy.
#6. MAIA Achieves Fast Track FDA Designation For Ateganosine Lung Cancer Therapy.
MAIA Biotechnology, Inc. received FDA Fast Track designation for ateganosine (THIO) in treating non-small cell lung cancer (NSCLC), a $34Bn market with significant unmet need.
Ateganosine, a first-in-class telomere-targeting molecule, disrupts cancer cell survival and enhances immune response.
This designation accelerates potential FDA approval, strengthening MAIA’s competitive edge.
If approved, ateganosine could reach market, advance cancer care, and secure exclusivity, underscoring MAIA’s pioneering role in innovative oncology treatments.
#7. MAIA Expands Global Phase 2 Trial Advancing Ateganosine Lung Cancer Therapy.
MAIA Biotechnology, Inc. announced the dosing of the first patient in Taiwan for the expansion of its pivotal Phase 2 THIO-101 trial, advancing ateganosine (THIO) for advanced non-small cell lung cancer (NSCLC).
This milestone extends the study’s reach across Asia and Europe, broadening access to a larger patient pool.
Interim results show ateganosine delivers a median overall survival of 17.8 months in heavily pre-treated patients—far surpassing the 5–6 months seen with chemotherapy.
Well-tolerated and first-in-class, ateganosine positions MAIA for leadership and first-mover advantage in the multi-Bn-dollar NSCLC market. -----
Coverage on MAIA Biotechnology, Inc. (NYSE American: MAIA) is now officially underway.
Be on the lookout for updates coming shortly. Talk soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 10/07/2025 and ending on 10/07/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC, or their members own shares of (MAIA:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia-2kQSt/#details | 
